Clinical Trials

Revolution Medicines' zoldonrasib delivers high response rates in trials for RAS G12D pancreatic cancer, offering a beacon of hope against a lethal disease.

New guidelines for ankle arthritis, a condition hitting younger workers hard, expose major gaps in medical research and a market ripe for innovation.

A massive financing round for deupirfenidone isn't just about a potential new IPF drug; it's a masterclass in biotech strategy, validating a model that promises value for all.

A new study for CRENESSITY could revolutionize care for infants with classic congenital adrenal hyperplasia, shifting the treatment paradigm and solidifying market leadership.

With a platform 300x faster than traditional methods, Hill Research has secured a major follow-on investment, signaling a new era for AI in life sciences.

For women with resistant ovarian cancer, options are few. A new drug, NTB-928, uses a dual-key design to unlock the immune system against tumors.

Oryzon Genomics secures a dual funding package, navigating market jitters to accelerate its pioneering cancer and psychiatric drug pipelines with EU backing.

Artelo's latest data on its non-opioid pain drug ART26.12 could unlock a massive market, but what are the real risks and rewards for this clinical-stage biotech?

After completing massive studies, the Utah firm is readying an FDA submission that could move gold-standard diagnostics from the lab to your local clinic.

A Singapore-based company has patented a device to end large incisions in colorectal surgery, promising fewer infections and faster patient recovery.

Intensity Therapeutics shows promising results for its cancer-killing drug, but can it navigate the biotech funding crunch and land a vital pharma partner?

With €7.5M from Europe’s top innovation fund, a Belgian startup is not just correcting vision—it’s turning the eye into a window for our overall health.

Caidya's union with Simbec-Orion isn't just another M&A deal. It’s a strategic play to build an end-to-end clinical partner for a complex global market.

Sarepta seeks full FDA approval for two Duchenne drugs, leaning on real-world evidence after a key trial missed its goal. A test case for rare disease innovation.

Exact Imaging's U.S. expansion signals a major shift. With technology rivaling MRI, micro-ultrasound is poised to make precision diagnostics more accessible.

New Phase 1 data suggests vamorolone delivers potent anti-inflammatory effects without the severe immunosuppression of traditional steroids at clinical doses.

Vistagen's Phase 3 trial for its novel anxiety nasal spray fails its main goal, but a surprising signal in severe cases prompts a high-stakes pivot.

Cumulus Neuroscience's at-home EEG platform shows remarkable patient adherence, promising to accelerate drug trials and reshape the fight against dementia.

Following a $103M funding round, Kinaset Therapeutics adds proven dealmakers to its board, signaling a strategic push for its novel inhaled asthma therapy.

Biotech firm R1 Therapeutics forms a star-studded advisory board to guide its promising kidney disease drug, AP306, into crucial Phase 2b trials.